aiqbenchInformații despre AI & calcul cuantic

Română · beta. Traducerea a fost făcută automat și este încă în curs de revizuire. Citește pagina în engleză

perspectiva aiqbenchProduse AI

OpenAI's acquisition of Orchestra Bio marks a strategic expansion of its Rosalind unit, integrating specialized AI agents designed to optimize clinical trial monitoring and regulatory workflows for pharma partners like Novo Nordisk and Moderna. This move shifts the focus from pure biological discovery to managing the operational complexity of drug development, aiming to reduce the typical 10–15 year timeline for bringing treatments to market.

Sursă care acoperăSiliconANGLE

OpenAI acquires Orchestra Bio to bring AI agents into drug development

SiliconANGLE20 octombrie 20264 min de cititArticolul și perspectiva sunt în engleză.

OpenAI Group PBC revealed today that it has acquired drug development software startup Orchestra Bio Inc. Orchestra builds artificial intelligence agents that help pharmaceutical teams keep development programs on track,. Its staff and technology will now sit inside OpenAI’s Rosalind life sciences unit. Much of OpenAI’s case for the deal comes down to how long […] The post OpenAI acquires Orchestra Bio to bring AI agents into drug development appeared first on SiliconANGLE.

OpenAI Group PBC revealed today that it has acquired drug development software startup Orchestra Bio Inc. Orchestra builds artificial intelligence agents that help pharmaceutical teams keep development programs on track,. Its staff and technology will now sit inside OpenAI’s Rosalind life sciences unit. Much of OpenAI’s case for the deal comes down to how long drugs take to reach patients. Getting a new medicine through to…

Extras afișat conform termenilor RSS ai publicației · 66 cuvinte · textul integral și figurile sunt pe site-ul publicației

Citește pe SiliconANGLE ↗Întreabă despre acest articol